Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?
Sergio Pecorelli* and Franco Odicino
Correspondence *Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Piazzale Spedali Civili 1, Brescia 25123, Italy
Email pecorelli@iol.it
This article has no abstract so we have provided the first paragraph of the full text.
Relapsed ovarian cancer is an incurable disease. Despite improvements in first-line treatment, up to 80% of patients diagnosed with advanced disease will ultimately relapse within 5 years from their initial diagnosis. The majority of these patients experience the recurrence more than 6 months from the end of primary platinum-based treatment; this timing generally defines their recurrent disease as 'platinum-sensitive'. Up to now, treatment decisions have been made on the basis of empirical results obtained from observational and controlled trials. Patients whose disease is platinum sensitive are usually re-treated with a platinum compound; patient response rates and progression-free and overall survival rates are highly correlated with the platinum-free interval.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.